GlobeNewswire

Compuware and SonarSource Unify Multi-Platform DevOps with Integrated COBOL Code Coverage Metrics

Dela

Mainframe-inclusive Continuous Code Quality Accelerates Digital Agility While De-Risking Generational Shift in Platform Stewardship

  • To be digitally agile, enterprises must more quickly and frequently update their core mainframe systems-while also shifting stewardship of those applications from retiring COBOL veterans to IT staff with mainstream skills.
     
  • Compuware has teamed with SonarSource to integrate accurate COBOL test coverage reporting into the automated QA processes they already use to support DevOps and Continuous Delivery.
     
  • This new integration empowers large enterprises to dramatically accelerate mainframe application quality and throughput without incurring additional risk-even as they "mainstream" stewardship of those systems.

DETROIT, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Compuware and SonarSource today released new integrations that empower enterprise DevOps teams to accurately track and validate code coverage of COBOL application testing-with the same ease and employing the same processes-as they do with Java and other more mainstream code.

This ability to automate code coverage tracking across platforms is yet another example of how Compuware is empowering enterprise IT to apply the same proven and essential Agile, DevOps and Continuous Integration/Continuous Delivery (CI/CD) disciplines to both core systems of record and systems of engagement.

Code coverage metrics provide insight into the degree to which source code is executed during a test-that is, which lines of code have or have not been executed, and what percentage of an application has or has not been tested. These measurements allow IT teams to understand the scope and effectiveness of their testing as code is promoted towards production.

The new integrations automatically feed code coverage results captured by Compuware Topaz for Total Test into SonarSource SonarQube-a popular continuous code quality solution used by more than 900 digitally innovative enterprises-giving DevOps teams an accurate, unified view of quality metrics and milestones across platforms.

Continuous code quality management across platforms is of extraordinary value to large enterprises-since their ability to bring new digital deliverables to market is often contingent on simultaneously updating code across both back-end mainframe systems of record and front-end mobile/web systems of engagement.

More specifically, integration between Topaz for Total Test and SonarQube now enables DevOps teams to:

  • Gain insight into the coverage of code being promoted for all application components across all platforms
  • Improve the rigor of digital governance with strong enforcement of mainframe QA policies for coding errors, data leakage, credential vulnerabilities and more
  • Shorten feedback loops to speed time-to-benefit and more promptly address shortfalls in COBOL skills and bottlenecks in mainframe DevOps processes

Topaz for Total Test captures code coverage metrics directly from the source code itself, rather than from a "source listing," as is the case with many outdated mainframe tools. This direct capture is more accurate and eliminates the need for development and test staff to understand the idiosyncrasies of how source listing models map to actual source code.

"Code coverage is such an integral part of continuous code quality that today's DevOps practitioners almost take it for granted," said Jason Bloomberg, President of agile digital transformation analyst firm Intellyx. "On the mainframe, however, code coverage has always been a difficult challenge. With today's announcement, Compuware and SonarSource bring mainframe code coverage into the DevOps era, further mainstreaming the mainframe."

"It is great that Compuware continues to develop a complete DevOps toolchain for COBOL. Adding code coverage is a major achievement and I am very happy this is happening," said Olivier Gaudin, CEO of SonarSource. "Our partnership with Compuware significantly enhances the ability of large enterprises to bring their mainframes into their cross-platform DevOps processes while still rigorously ensuring the quality of their core enterprise applications."

Compuware has also simplified the configuration and use of Xpediter Code Coverage-making it much easier for COBOL novices and experts alike to understand the effectiveness of their testing. When running automated tests and debugging code via Topaz's intuitive Eclipse interface, covered and uncovered code is highlighted so developers can quickly spot areas that need attention, just as they do in Java.

Today's announcement further delivers on Compuware's promise to mainstream the mainframe; that is, providing a familiar and intuitive mainframe development environment-integrated with state-of-the-art DevOps tools-for developers newly engaged as mainframe application stewards. The announcement marks the 13th consecutive quarter that Compuware has delivered significant innovation towards this modernization effort.

"Our customers run their businesses on the mainframe, so their proven COBOL applications are of extraordinary value and importance to them," said Chris O'Malley, CEO of Compuware. "That's why we are serving our customers by aggressively delivering the new solutions they need to achieve their ambitious goals for digital transformation, just like an authentic mainframe software partner should."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum